معاملات المطّلعين

Exercise of in-the-money or at-the-money derivative security

• F2 On October 30, 2026 (the Exercise Date), DWP exercised in full, on a cashless basis pursuant to Section 10 of the Pre-Funded Warrant, Pre-Funded Warrants to purchase 11,236,631 shares of Class A Common Stock at an exercise price of $0.0001 per share. No cash was paid by DWP in connection with the exercise.
• F1 Daewoong Co., Ltd. (DWC) owns approximately 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd. (DWP), a company organized under the laws of the Republic of Korea, and may be deemed to have voting and dispositive power over, and to beneficially own, the securities of the Issuer held directly by DWP. The securities reported herein are held directly by DWP and are reported by DWC as indirectly beneficially owned, consistent with the Form 3 filed by DWC with respect to the Issuer on January 29, 2026. DWC disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein, and the filing of this statement shall not be deemed an admission that DWC is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Other acquisition or disposition (describe transaction)

• F3 Represents 3,822 shares of Class A Common Stock withheld by the Issuer in satisfaction of the aggregate exercise price of the Pre-Funded Warrants in accordance with the net exercise formula set forth in the Pre-Funded Warrant, based on the closing sale price of $0.294 per share on October 29, 2026, the trading day immediately preceding the Exercise Date. As a result of the cashless exercise, 11,232,809 shares of Class A Common Stock were issued to DWP.
• F1 Daewoong Co., Ltd. (DWC) owns approximately 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd. (DWP), a company organized under the laws of the Republic of Korea, and may be deemed to have voting and dispositive power over, and to beneficially own, the securities of the Issuer held directly by DWP. The securities reported herein are held directly by DWP and are reported by DWC as indirectly beneficially owned, consistent with the Form 3 filed by DWC with respect to the Issuer on January 29, 2026. DWC disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein, and the filing of this statement shall not be deemed an admission that DWC is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Exercise of in-the-money or at-the-money derivative security

• F2 On October 30, 2026 (the Exercise Date), DWP exercised in full, on a cashless basis pursuant to Section 10 of the Pre-Funded Warrant, Pre-Funded Warrants to purchase 11,236,631 shares of Class A Common Stock at an exercise price of $0.0001 per share. No cash was paid by DWP in connection with the exercise.
• F4 The Pre-Funded Warrants were exercisable at any time on or after January 21, 2026 and did not expire until exercised in full. Following the exercise described in footnotes (2) and (3), no Pre-Funded Warrants remain outstanding.
• F1 Daewoong Co., Ltd. (DWC) owns approximately 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd. (DWP), a company organized under the laws of the Republic of Korea, and may be deemed to have voting and dispositive power over, and to beneficially own, the securities of the Issuer held directly by DWP. The securities reported herein are held directly by DWP and are reported by DWC as indirectly beneficially owned, consistent with the Form 3 filed by DWC with respect to the Issuer on January 29, 2026. DWC disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein, and the filing of this statement shall not be deemed an admission that DWC is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Open market or private purchase of non-derivative or derivative security

• F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.1975 to $0.2164 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 Represents an award of restricted stock units (RSUs) granted on June 17, 2026 (the Grant Date). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 Represents an award of restricted stock units (RSUs) granted on June 17, 2026 (the Grant Date). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 Represents an award of restricted stock units (RSUs) granted on June 17, 2026 (the Grant Date). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 Represents an award of restricted stock units (RSUs) granted on June 17, 2026 (the Grant Date). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 Represents an award of restricted stock units (RSUs) granted on June 17, 2026 (the Grant Date). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 Represents an award of restricted stock units granted on April 1, 2026 (the Grant Date), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F2 Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the Grant Date) that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F2 Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the Grant Date) that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F2 Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the Grant Date) that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 Represents an award of restricted stock units granted on February 17, 2026 (the Grant Date), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 Represents an award of restricted stock units granted on February 17, 2026 (the Grant Date), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 Represents an award of restricted stock units granted on February 17, 2026 (the Grant Date), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 Represents an award of restricted stock units granted on February 17, 2026 (the Grant Date), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.